On March 6, 2018 Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, reported that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the following investor conferences (Press release, Myovant Sciences, MAR 6, 2018, http://investors.myovant.com/news-releases/2018/03-06-2018-220102504 [SID1234524457]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 38th Annual Healthcare Conference on Monday March 12, 2018 at 2:50 p.m. ET
Barclays Global Healthcare Conference on Tuesday March 13, 2018 at 10:15 a.m. ET

The events will be webcast live and may be accessed via the Events page under the Investors and Media section of Myovant’s website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

On March 6, 2018 Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported it will webcast its corporate presentation at the 38th Annual Cowen Healthcare Conference in Boston on Monday, March 12, 2018 at 1:30 p.m. ET (Press release, , JUN 6, 2018, View Source [SID1234524623]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of both the presentation and breakout session will be accessible from Keryx’s website at View Source within the Investor Relations section under "webcasts and presentations." Archived versions of the webcasts will be available for at least 15 days following the conclusion of each session

The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83 rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients (Press release, mAbxience, MAR 6, 2018, View Source [SID1234525381])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

.
The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity at pharmacokinetic level as required by regulatory agencies, a population pharmacokinetic analysis was performed to compare RTXM83 with respect to the reference product. For this purpose, 5,431 serum samples from 251 recruited patients were used. The systemic exposure of RTXM83 and its associated variability were similar to those for rituximab reference, demonstrating PK similarity. The PD similarity of RTXM83 and rituximab reference product was also demonstrated.

Protalix has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Protalix, 2018, MAR 6, 2018, View Source [SID1234524430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 6, 2018 AVEO Oncology (NASDAQ: AVEO) reported that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time (Press release, AVEO, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336395 [SID1234524409]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.